Tag: BIO TECH

Esperion Therapeutics (NASDAQ: ESPR) has presented results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results… [Read More]

Medical technology company, HeartSciences (Nasdaq: HSCS), has announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening… [Read More]

Biopharmaceuticals company, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) has failed to meet primary and secondary endpoints in a Phase 2b study of zunsemetinib (ATI-450), an investigational… [Read More]

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has enrolled the first participant in an investigator-initiated Phase 2 study of TNX-1900 (intranasal potentiated oxytocin) for improving bone… [Read More]

Lipella Pharmaceuticals (Nasdaq: LIPO) has received Orphan Drug Designation for its LP-310 drug candidate for oral Graft-versus-Host Disease (GvHD). LP-310 is the company’s clinical stage… [Read More]

Leading regenerative medicine company, BioStem Technologies (OTC:BSEM) has secured a CMS Q code for its VENDAJE AC® structural tissue allograft product. The Healthcare Common Procedure… [Read More]

Lucid Diagnostics Inc. (Nasdaq: LUCD) a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM) has launched the next generation of its EsoGuard® Esophageal DNA test for… [Read More]

Healthcare technology company, CareCloud (Nasdaq: CCLD), has been selected by Ultrasound Express to help enhance its patient experience and streamline administrative processes. CareCloud’s talkEHR platform… [Read More]

Biopharmaceutical company, Cybin Inc. (NYSE American: CYBN), has announced interim results for its Phase 2 clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog. CYB003… [Read More]

GeoVax Labs (Nasdaq: GOVX) has commenced its planned site expansion for a Phase 2 clinical trial investigating its next-generation COVID vaccine, GEO-CM04S1, as a primary… [Read More]